UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

105-LB: Safety and Performance of an Advanced Hybrid Closed-Loop (AHCL) Algorithm with Ultra-rapid Lispro (URLi) and Lispro

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial

Diabetes, obesity & metabolism, 2023-01, Vol.25 (1), p.89-97

2023

Volltextzugriff (PDF)

38-OR: Glycemic Control with Ultrarapid Lispro (URLi) vs. Lispro in Children and Adolescents with T1D: PRONTO-Peds

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Initiating insulin: How to help people with type 2 diabetes start and continue insulin successfully

International journal of clinical practice (Esher), 2017-08, Vol.71 (8), p.e12973-n/a

2017

Volltextzugriff (PDF)

Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)

Diabetes therapy, 2019-02, Vol.10 (1), p.189-203

2019

Volltextzugriff (PDF)

Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Diabetes therapy, 2018-04, Vol.9 (2), p.827-837

2018

Volltextzugriff (PDF)

Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (<65, ≥65 Years)

Canadian journal of diabetes, 2016-10, Vol.40 (5), p.S40-S40

2016

Volltextzugriff (PDF)

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2

GaBI Journal, 2018-06, Vol.7 (2), p.56-62

2018

Volltextzugriff (PDF)

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine

Diabetes therapy, 2017-06, Vol.8 (3), p.545-554

2017

Volltextzugriff (PDF)

Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T2DM: The ELEMENT 2 Study

Canadian journal of diabetes, 2014-10, Vol.38 (5), p.S49-S49

2014

Volltextzugriff (PDF)

Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study

Canadian journal of diabetes, 2014-10, Vol.38 (5), p.S53-S53

2014

Volltextzugriff (PDF)

Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1DM or T2DM

Canadian journal of diabetes, 2014-10, Vol.38 (5), p.S52-S53

2014

Volltextzugriff (PDF)

Utilization of a multidisciplinary team for inpatient diabetes care

Critical care nursing quarterly, 2004-04, Vol.27 (2), p.185-188

2004

Volltextzugriff (PDF)

Clinical analytics equal better systemwide outcomes

Nursing management, 2007-12, Vol.38 (12), p.44-48

2007

Volltextzugriff (PDF)

CA-095 - Efficacité et tolérance similaires de l’insuline glargine LY2963016 et de l’insuline glargine (Lantus®) chez les patients diabétiques de type 2 dans les groupes d’âge (< 65 ans, ≥ 65 ans)

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A83-A83

2017

Volltextzugriff (PDF)

Efficacité et tolérance similaires de l’insuline glargine LY2963016 et de l’insuline glargine (Lantus ® ) chez les patients diabétiques de type 2 dans les groupes d’âge (< 65 ans, ≥ 65 ans)

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A83

2017

Volltextzugriff (PDF)

Similar Efficacy and Safety of Basaglar.sup.[R] and Lantus.sup.[R] in Patients with Type 2 Diabetes in Age Groups ( 65 Years, [greater than or equal to] 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Diabetes therapy, 2018-04, Vol.9 (2), p.827

2018

Volltextzugriff (PDF)

108 - Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (<65, ≥65 Years)

Canadian journal of diabetes, 2016-10, Vol.40 (5), p.S40-S40

2016

Volltextzugriff (PDF)

Biosimilar insulins: What do you need to know?

International diabetes nursing, 2017-01, Vol.14 (1), p.32-35

2017

Volltextzugriff (PDF)

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus^sup ^ Insulin Glargine

Diabetes therapy, 2017-06, Vol.8 (3), p.545

2017

Volltextzugriff (PDF)

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus.sup.[R] Insulin Glargine

Diabetes therapy, 2017-06, Vol.8 (3), p.545

2017

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

105-LB: Safety and Performance of an Advanced Hybrid Closed-Loop (AHCL) Algorithm with Ultra-rapid Lispro (URLi) and Lispro

Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial

38-OR: Glycemic Control with Ultrarapid Lispro (URLi) vs. Lispro in Children and Adolescents with T1D: PRONTO-Peds

1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)

Initiating insulin: How to help people with type 2 diabetes start and continue insulin successfully

Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)

Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (<65, ≥65 Years)

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine

Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T2DM: The ELEMENT 2 Study

Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study

Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1DM or T2DM

Utilization of a multidisciplinary team for inpatient diabetes care

Clinical analytics equal better systemwide outcomes

CA-095 - Efficacité et tolérance similaires de l’insuline glargine LY2963016 et de l’insuline glargine (Lantus®) chez les patients diabétiques de type 2 dans les groupes d’âge (< 65 ans, ≥ 65 ans)

Efficacité et tolérance similaires de l’insuline glargine LY2963016 et de l’insuline glargine (Lantus ® ) chez les patients diabétiques de type 2 dans les groupes d’âge (< 65 ans, ≥ 65 ans)

Similar Efficacy and Safety of Basaglar.sup.[R] and Lantus.sup.[R] in Patients with Type 2 Diabetes in Age Groups ( 65 Years, [greater than or equal to] 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

108 - Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (<65, ≥65 Years)

Biosimilar insulins: What do you need to know?

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus^sup ^ Insulin Glargine

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus.sup.[R] Insulin Glargine

Suchergebnisse filtern